You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people

Article type: Research Article

Authors: Wang, Yua; * | Jiang, Xiaoronga | Dong, Shaoliangb | Shen, Jiankunb | Yu, Haixiaa | Zhou, Jic | Li, Jinc; d | Ma, Hongboc | He, Ellenc | Skog, Svenc; *

Affiliations: [a] Health Management Center of PLA 180 Hospital, Quanzhou, Fujian, China | [b] Medicine Management Department, PLA 180 Hospital, Quanzhou, Fujian, China | [c] Sino-Swed Molecular Bio-Medicine Research Institute, Shanghai, China | [d] Department of Ophthalmology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, Guangdong, China

Correspondence: [*] Corresponding authors: Sven Skog, Sino-Swed Molecular Bio-Medicine Research Institute, Shanghai 299333, China. Tel.: +86 46736402152; Fax: +86 75526031330; E-mail: [email protected]; Yu Wang, Health Management Center of PLA 180 Hospital, Quanzhou 362000, Fujian, China. Tel.: +86 133313835652; Fax: +86 59522761738; E-mail: [email protected]

Keywords: Thymidine kinase 1 (TK1), CEA, AFP, health screening

DOI: 10.3233/CBM-160594

Journal: Cancer Biomarkers, vol. 16, no. 4, pp. 529-536, 2016

Published: 13 April 2016
Get PDF open access

Abstract

BACKGROUND:

The World Health Organization (WHO) has estimated that the number of cancer patients will increase by about 70% during the next 25 years world-wide. To deal with this problem, WHO has suggested a focus on prevention of tumor incidence and health screening for early detection of people with tumors.

OBJECTIVE:

To investigate the use of thymidine kinase 1 (TK1), CEA and AFP in serum to discover people with malignant tumors through health cancer screening.

METHODS:

Of a cohort in 486,085 people of a routine health screening at the Health Centre, Fujun 180 Hospital, Quanzhou city, China, 56,286 people were investigated according to the presence of cancer during 2009-2014. The concentration of CEA and AFP were determined by an electrochemiluminescence immunoassay from Roche Diagnostics e601GmbH and STK1 by a commercial kit based on an enhanced chemiluminescent dot blot assay.

RESULTS:

The cancer incident rate increased from 0.048/100,000 to 0.220/100,000. The most common types of tumors were those of the liver, cervix and lung. STK1 correlated to tumor growth rate, was more sensitive than CEA and AFP for discovering people with malignant tumors and more sensitive among people who had diagnosis of malignant tumor. STK1 was also a prognostic biomarker for death at 10-40 months follow-up, while CEA and AFP were not. A combination of these markers increased the sensitivity by about 30%.

CONCLUSION:

STK1 is a reliable biomarker for discovering people with malignant tumors in cancer screening.

References

[1] 

Chen W., Estimation of cancer incidence and mortality in China in 2004-2005, Chinese J Oncol 31: ((2009) ), 664-668.

[2] 

Stewart B.W., and Wild Ch.P., World Cancer Report 2014, ISBN 978-92-832-0429-9.

[3] 

Chen W., , Zheng R., , Zeng H. et al., Trend analysis and projection of cancer incidence in China between 1989 and 2008, Chinese J Oncol 34: ((2012) ), 517-524.

[4] 

Cigna, Tumor markers for cancer in Cigna medical coverage policy, 1/15/((2015) ), 1-5.

[5] 

Sherley J.L., and Kelly T.J., Regulation of human thymidine kinase during the cell cycle, J Biol Chem 263: ((1988) ), 8350-8358.

[6] 

Al-Madhoun A., , Tjarks W., and Eriksson S., The role of thymidine kinases in the activation of pyrimidine nucleoside analogues, Mini Rev Med Chem 4: ((2004) ), 341-350.

[7] 

Gasparri F., , Wang N., , Skog S., , Galvani A., and Eriksson S., Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays, Eur J Cell Biol 88: ((2009) ), 779-785.

[8] 

Chen Y.L., , Eriksson S., and Chang Z.F., Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage, J Biol Chem 285: ((2010) ), 27327-27335.

[9] 

Wu C.J., , Yang R.J., , Zhou J., , Bao S., , Zou L., , Mao Y.R., , He Q., Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1, J Immuno Method, 277: ((2003) ), 157-169.

[10] 

Zou L., , Zhang P.G., , Zou S., , Li Y., , He Q., The half-life of cytosolic thymidine kinase in serum by ECL dot bolt potential marker for monitoring the response to surgery of patients with gastric cancer, Int J Biolog Marker, 17: ((2002) ), 135-140.

[11] 

Pan Z.L., , Ji X.Y., , Shi Y.M., , Zhou J., , He E., , Skog S., Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol, 136: ((2010) ), 1193-1199.

[12] 

Chen F.Y., , Tang L.L., , Xia T., , He E., , Hu G.Z., , Li Y., , Zhan M., , Zhou J., , Eriksson S., , Skog S., Serum thymidine kinase 1 levels predict cancer.free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer, Molecular and Clinical Oncology 1: ((2013) ), 894-902.

[13] 

Topolcan O., and Holubec L., The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn 2: ((2008) ), 129-141.

[14] 

Aufderklamm S., , Todenhöfer T., , Gakis G., , Kruck S., , Hennenlotter J., , Stenzl A., and Schwentner C., Thymidine kinase and cancer monitoring, Cancer Lett 316: ((2012) ), 6-10.

[15] 

Zhang G.Q., , Jiao S.C., and Wei X.F., Serum thymidine kinase 1: A proliferation marker for neoplasms in oncologic monitoring of elderly people, J Modern Oncol 16: ((2008) ), 831-832.

[16] 

Xu X.H., , Zhang Y.M., , Shu X.H., , Wang Z.W., , Zhou Y.L., , Wen H.K., , He F., , He E., , Skog S., Serum thymidine kinase 1 reflects the progression of premalignant and malignant tumors during therapy, Molecular Medicine Reports 1: ((2008) ), 705-712.

[17] 

Chen Z.H., , Zhou H., , Tian N.B. et al., Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumours, Anticancer Res 28: ((2008) ), 3897-3907.

[18] 

Zhang X.H., , Yang J.R., , Fu X.Y., , Liu H.X., , Yun X., , Song B., , Zhang M., , He E., and Skog S., The significance of serum thymidine kinase 1 for the risk screening of cancer development in pre-cancerous diseases, Chin J Health Manag 4: ((2008) ), 35-38.

[19] 

Huang S.Q., , Lin J., , Guo N., , Zhang M., , Yun X., , Liu S., , Zhou J., , He E., and Skog S., Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression, Asian Pac J Cancer Prev 12: ((2011) ), 497-505.

[20] 

Chen Z.H., , Huang S.Q., , Wang Y., , Yang A.Z., , Wen J., , Xu X.H., , Chen Y., , Chen Q.B., , Wang Y.H., , Hee E., , Zhou J., and Skog S., Serological thymidine kinase 1 is a biomarker for early detection of tumours - a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay, Sensors 11: ((2011) ), 1106411080.

[21] 

Zhou J., , He E., and Skog S., The proliferation marker thymidine kinase 1 in clinical use (Review), Mol Clin Oncol 1: ((2013) ), 18-28.

[22] 

Wu J.T., Circulating Tumor Markers of the New Millennium. AACC Press, New York, ((2002) ), pp. 115-117.

[23] 

Chinese Cancer Registration Annual Report, ((2011) ), National Cancer Center, Disease Prevention and Control Bureau, Ministry of China.

[24] 

Zhang Z.J., , Zheng Y.P., , Lin Y.F., , Mei X.Q., Clinical detecting application of TK1 in the diagnosis of common malignant tumors, Int. J. Lab. Med. 35: ((2014) ), 2636-2637.

Show more